DK3452465T3 - Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme - Google Patents
Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme Download PDFInfo
- Publication number
- DK3452465T3 DK3452465T3 DK17731278.2T DK17731278T DK3452465T3 DK 3452465 T3 DK3452465 T3 DK 3452465T3 DK 17731278 T DK17731278 T DK 17731278T DK 3452465 T3 DK3452465 T3 DK 3452465T3
- Authority
- DK
- Denmark
- Prior art keywords
- diaminoquinoline
- derivatives
- substituted
- treatment
- proliferative diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331844P | 2016-05-04 | 2016-05-04 | |
| PCT/IB2017/052614 WO2017191599A1 (en) | 2016-05-04 | 2017-05-04 | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3452465T3 true DK3452465T3 (da) | 2021-02-08 |
Family
ID=59078115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17731278.2T DK3452465T3 (da) | 2016-05-04 | 2017-05-04 | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10577362B2 (da) |
| EP (1) | EP3452465B1 (da) |
| JP (1) | JP6969800B2 (da) |
| CN (1) | CN109415343A (da) |
| CA (1) | CA3023032A1 (da) |
| DK (1) | DK3452465T3 (da) |
| ES (1) | ES2849560T3 (da) |
| HR (1) | HRP20210169T1 (da) |
| SI (1) | SI3452465T1 (da) |
| WO (1) | WO2017191599A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108456183A (zh) * | 2018-03-09 | 2018-08-28 | 上海工程技术大学 | Gedatolisib的制备方法及中间体 |
| EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
| EP4349336A1 (en) * | 2022-10-04 | 2024-04-10 | Genoscience Pharma | Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers |
| CN116751186A (zh) * | 2022-12-23 | 2023-09-15 | 南京知和医药科技有限公司 | 一种***受体调节剂的制备及其用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US6262059B1 (en) * | 1995-06-07 | 2001-07-17 | Cell Pathways, Inc. | Method of treating a patient having precancerous lesions with quinazoline derivatives |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| AR028782A1 (es) * | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
| US6548508B2 (en) * | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6787558B2 (en) * | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| MXPA04007402A (es) | 2002-02-01 | 2005-06-17 | Ariad Gene Therapeutics Inc | Compuestos que contienen fosforo y usos de los mismos. |
| DK1482924T3 (da) | 2002-03-05 | 2008-09-29 | Merck Frosst Canada Ltd | Cathepsin-cystein-protease-inhibotorer |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| BR0312204A (pt) * | 2002-06-27 | 2005-04-26 | Schering Ag | Antagonista de receptor ccr5 de quinolina substituìda |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| US7759336B2 (en) * | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| CA2518398A1 (en) | 2003-03-10 | 2004-09-23 | Schering Corporation | Heterocyclic kinase inhibitors: methods of use and synthesis |
| CN1784229A (zh) * | 2003-03-10 | 2006-06-07 | 先灵公司 | 杂环激酶抑制剂:使用方法与合成 |
| US20080119515A1 (en) * | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| US7888364B2 (en) | 2004-09-02 | 2011-02-15 | Curis, Inc. | Pyridyl inhibitors of hedgehog signalling |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN101300249A (zh) * | 2005-06-10 | 2008-11-05 | 詹森药业有限公司 | 氨基喹啉和氨基喹唑啉激酶调节剂 |
| US20070116643A1 (en) | 2005-07-01 | 2007-05-24 | Concert Pharmaceuticals Inc. | Novel aryloxypropanamines |
| WO2007005643A2 (en) | 2005-07-01 | 2007-01-11 | Concert Pharmaceuticals Inc. | Novel aryloxyphenylpropanamines |
| EP2324886A1 (en) | 2005-07-29 | 2011-05-25 | Concert Pharmaceuticals Inc. | Novel deuterated analogues of tadalafil |
| KR101380190B1 (ko) | 2005-07-29 | 2014-04-11 | 콘서트 파마슈티컬즈, 인크. | 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체 |
| WO2007114323A1 (ja) * | 2006-04-04 | 2007-10-11 | Taisho Pharmaceutical Co., Ltd. | アミノピロリジン化合物 |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| ES2439705T3 (es) | 2007-10-25 | 2014-01-24 | Genentech, Inc. | Proceso para la preparación de compuestos de tienopirimidina |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| JP2012531436A (ja) * | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用 |
| CN102127070A (zh) * | 2010-01-15 | 2011-07-20 | 山东轩竹医药科技有限公司 | 吡啶并环衍生物 |
| SG11201506385WA (en) * | 2013-03-18 | 2015-10-29 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
| TR201900148T4 (tr) * | 2014-10-31 | 2019-02-21 | Genoscience Pharma Sas | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. |
-
2017
- 2017-05-04 SI SI201730626T patent/SI3452465T1/sl unknown
- 2017-05-04 EP EP17731278.2A patent/EP3452465B1/en active Active
- 2017-05-04 DK DK17731278.2T patent/DK3452465T3/da active
- 2017-05-04 JP JP2018557419A patent/JP6969800B2/ja active Active
- 2017-05-04 CA CA3023032A patent/CA3023032A1/en active Pending
- 2017-05-04 US US16/098,546 patent/US10577362B2/en active Active
- 2017-05-04 ES ES17731278T patent/ES2849560T3/es active Active
- 2017-05-04 WO PCT/IB2017/052614 patent/WO2017191599A1/en unknown
- 2017-05-04 CN CN201780038986.3A patent/CN109415343A/zh active Pending
-
2021
- 2021-02-02 HR HRP20210169TT patent/HRP20210169T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190144437A1 (en) | 2019-05-16 |
| CN109415343A (zh) | 2019-03-01 |
| US10577362B2 (en) | 2020-03-03 |
| ES2849560T3 (es) | 2021-08-19 |
| EP3452465A1 (en) | 2019-03-13 |
| JP2019514951A (ja) | 2019-06-06 |
| SI3452465T1 (sl) | 2021-04-30 |
| CA3023032A1 (en) | 2017-11-09 |
| JP6969800B2 (ja) | 2021-11-24 |
| HRP20210169T1 (hr) | 2021-03-19 |
| WO2017191599A1 (en) | 2017-11-09 |
| EP3452465B1 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3889145T3 (da) | 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3383363T3 (da) | Topiske farmaceutiske formuleringer til behandling af inflammatorisk-relaterede tilstande | |
| DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| DK3439635T3 (da) | Formuleringer til behandling af fast tumor | |
| ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3532067T3 (da) | Liposomal formulering til anvendelse til behandling af cancer | |
| DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| DK3606926T3 (da) | Heteroaromatiske forbindelser anvendelige i terapi | |
| DK3478679T3 (da) | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |